Jane Finch
Overview
Explore the profile of Jane Finch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mizobuchi M, Nakamura H, Tokumoto M, Finch J, Morrissey J, Liapis H, et al.
J Steroid Biochem Mol Biol
. 2010 Mar;
121(1-2):188-92.
PMID: 20236614
Cardiovascular complications are the leading cause of death in patients with chronic kidney disease (CKD). Traditional causes such as diabetes, smoking, aging and hypertension do not fully explain the high...
2.
Husain K, Ferder L, Mizobuchi M, Finch J, Slatopolsky E
Am J Nephrol
. 2008 Nov;
29(5):465-72.
PMID: 19033720
Aims: This study investigated the protective effect of the angiotensin-converting enzyme inhibitor, enalapril, and the vitamin D analog, paricalcitol, alone or in combination, on cardiac oxidative stress in uremic rats....
3.
Slatopolsky E, Liapis H, Finch J
Kidney Int
. 2005 Dec;
68(6):2809-13.
PMID: 16316357
Background: The loss of renal function in chronic kidney disease (CKD) patients leads to a variety of metabolic disturbances that promote the development of secondary hyperparathyroidism (SH) and bone disease....
4.
Cozzolino M, Staniforth M, Liapis H, Finch J, Burke S, Dusso A, et al.
Kidney Int
. 2003 Oct;
64(5):1653-61.
PMID: 14531797
Background: In chronic renal failure (CRF), hyperphosphatemia and an elevated calcium-phosphate product are associated with vascular calcification and increased cardiovascular morbidity and mortality. Previous data have demonstrated that 3-month treatment...
5.
Slatopolsky E, Cozzolino M, Lu Y, Finch J, Dusso A, Staniforth M, et al.
Kidney Int
. 2003 May;
63(6):2020-7.
PMID: 12753289
Background: The control of parathyroid hyperplasia and high circulating parathyroid hormone (PTH) levels is crucial in preventing secondary hyperparathyroidism (SH) in renal failure. Parathyroid gland enlargement and elevated levels of...
6.
Slatopolsky E, Finch J, Brown A
Kidney Int Suppl
. 2003 May;
(85):S83-7.
PMID: 12753273
Background: 1,25-(OH)2D3 (calcitriol) controls parathyroid gland growth and suppresses the synthesis and secretion of parathyroid hormone. Because of this, 1,25-(OH)2D3 has been used successfully for the treatment of secondary hyperparathyroidism,...
7.
Cozzolino M, Dusso A, Liapis H, Finch J, Lu Y, Burke S, et al.
J Am Soc Nephrol
. 2002 Aug;
13(9):2299-308.
PMID: 12191974
The control of serum phosphorus (P) and calcium-phosphate (Ca x P) product is critical to the prevention of ectopic calcification in chronic renal failure (CRF). Whereas calcium (Ca) salts, the...
8.
Brown A, Finch J, Slatopolsky E
J Lab Clin Med
. 2002 May;
139(5):279-84.
PMID: 12032488
19-Nor-1,25-dihydroxyvitamin D(2) (19-norD(2)) a less calcemic and phosphatemic analog of 1,25-dihydroxyvitamin D (1,25[OH](2)D(3)), is approved for the treatment of secondary hyperparathyroidism in patients with kidney failure. We have previously demonstrated...
9.
Brown A, Finch J, Takahashi F, Slatopolsky E
J Am Soc Nephrol
. 2000 Oct;
11(11):2088-2094.
PMID: 11053485
19-Nor-1,25(OH)(2)D(2) (19-norD(2)) has been shown to suppress parathyroid hormone effectively, but with lower calcemic activity than 1,25(OH)(2)D(3). The present study investigated potential mechanisms to explain the reduced calcemic response to...